
Shebli Atrash, MD, MS, FACP, is a hematologist and medical oncologist specializing in plasma cell disorders and cellular therapy. He is an Associate Professor in the Department of Internal Medicine at Wake Forest University School of Medicine and a physician in the Plasma Cell Disorders Division of the Department of Hematologic Oncology & Blood Disorders at Atrium Health Levine Cancer Institute. His clinical focus includes plasma cell disorders, cellular and immune-based therapies, and hematopoietic stem cell transplantation. An active clinical investigator, Dr. Atrash’s research centers on the outcomes of novel immunotherapies, risk-adapted and response-guided treatment strategies, and equitable access to advanced cancer therapies. He serves as lead principal investigator for early-phase, cellular therapy, and investigator-initiated clinical trials. His achievements include recognition as a Fellow of the American College of Physicians and leadership roles with the International Myeloma Working Group, the SWOG Myeloma Committee, and the US Myeloma Innovations Research Collaborative, along with active service in ASH, ASCO, and ASTCT. Dr. Atrash earned his medical degree from Damascus University, completed his residency in Internal Medicine at Saint Barnabas Hospital/Albert Einstein College of Medicine, and completed his fellowship in Hematology and Medical Oncology at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.
Associate Professor
Medical School
1998 – 2004
Residency
2008 – 2011
Fellowship
2014 – 2017